Please login to the form below

Not currently logged in
Email:
Password:

Merck suspends Stimuvax programme

Merck has temporarily suspended its Stimuvax clinical programme after a patient developed encephalitis, an acute inflammation of the brain

Merck has temporarily suspended its Stimuvax (BLP25 liposome vaccine) clinical programme on a worldwide scale after a patient developed encephalitis, an acute inflammation of the brain.

The German pharmaceutical company has said that "effective immediately" all enrollments into trials and treatment of patients in current trials will be put on hold.

The decision was taken "in alignment with the US Food and Drug Administration's (FDA) clinical hold placed on the Investigational New Drug (IND) application for Stimuvax," according to Merck in a statement.

The Stimuvax vaccine is currently being tested in both phase II and phase III clinical trials for the treatment of non-small cell lung carcinoma (NSCLC) and breast cancer after being granted fast-track status in September 2004 by the FDA.

The patient who developed encephalitis was participating in a phase II exploratory trial using the vaccine in patients with multiple myeloma. This trial involved an intensified schedule of low-dose cyclophosphamide, a treatment not used in other Stimuvax studies.

The affected ongoing trials affected by the suspension include the NSCLC studies START and INSPIRE and the breast cancer study STRIDE.

"The company considers patient safety of paramount importance," said Merck "and will continue to work closely with the regulatory authorities, particularly with the FDA, to evaluate the implications of the adverse reaction on the clinical development programme for Stimuvax and determine the most suitable course of action."

23rd March 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics